FY2026 EPS Forecast for Delcath Systems Increased by Analyst

Delcath Systems, Inc. (NASDAQ:DCTH) – HC Wainwright lifted their FY2026 earnings per share estimates for shares of Delcath Systems in a report issued on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.13 for the year, up from their previous forecast of ($0.17). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2026 earnings at ($0.10) EPS, Q3 2027 earnings at $0.22 EPS and FY2027 earnings at $0.33 EPS.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Monday, November 9th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.26. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%. The business had revenue of $35.10 million during the quarter, compared to analysts’ expectations of $25.99 million.

Several other analysts also recently weighed in on DCTH. Weiss Ratings downgraded Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. BTIG Research increased their target price on shares of Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Zacks Research downgraded shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $29.33.

Delcath Systems Trading Up 8.3%

Shares of Delcath Systems stock opened at $21.77 on Thursday. The firm has a market cap of $755.40 million, a P/E ratio of 136.06 and a beta of 0.62. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $22.33. The stock’s fifty day moving average price is $15.71 and its 200-day moving average price is $12.59.

Institutional Trading of Delcath Systems

Hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its holdings in shares of Delcath Systems by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock valued at $1,417,000 after acquiring an additional 21,069 shares during the period. Alps Advisors Inc. raised its position in shares of Delcath Systems by 30.3% in the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock worth $729,000 after acquiring an additional 10,600 shares in the last quarter. Kopp Family Office LLC bought a new position in shares of Delcath Systems in the 3rd quarter worth $450,000. Integrated Wealth Concepts LLC bought a new position in shares of Delcath Systems in the 2nd quarter worth $48,000. Finally, IFP Advisors Inc purchased a new stake in shares of Delcath Systems during the 2nd quarter worth $52,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Key Headlines Impacting Delcath Systems

These are some of the DCTH headlines that stood out recently:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, compared with analysts’ consensus estimate of a $0.09 loss, and revenue of $35.1 million versus expectations of $26.0 million. The earnings beat has been cited alongside the stock’s recent advance. Article: Delcath Systems Stock Price Up on Better-Than-Expected Earnings
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast from a loss of $0.17 to a profit of $0.13, and its FY2027 estimate from $0.12 to $0.33. It also improved its Q4 2026 forecast, narrowing the projected loss to $0.10 per share from $0.13. The firm maintains a Buy rating and a $36 price target. Article: Delcath Systems Gets a Buy from H.C. Wainwright
• Positive Sentiment: Delcath will be featured on “Health Uncensored with Dr. Drew” in a segment about advances in liver-directed cancer treatment, offering potential public visibility for its approach. Article: Delcath Systems to Be Featured on Health Uncensored with Dr. Drew

Delcath Systems Company Profile

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.